Background
Rosmantuzumab (OMP-131R10) is an anti-R-spondin 3 (RSPO3) humanized monoclonal antibody. Rosmantuzumab can be used for the research of advanced telapsed and refractory solid tumors.• Intra- and Inter-cellular Rewiring of the Human Colon during Ulcerative Colitis., PMID:31348891• Hepatic stellate cells control liver zonation, size and functions via R-spondin 3., PMID:40074890• Organoid cultures of early-onset colorectal cancers reveal distinct and rare genetic profiles., PMID:32217638• Endothelial RSPO3 mediates pulmonary endothelial regeneration by LGR4-dependent activation of β-catenin and ILK signaling pathways after inflammatory vascular injury., PMID:38677673• The role of R-spondin proteins in cancer biology., PMID:34663878• Estradiol and RSPO3 regulate vertebral trabecular bone mass independent of each other., PMID:35068191• RSPO3 regulates the radioresistance of Non-Small cell lung cancer cells via NLRP3 Inflammasome-Mediated pyroptosis., PMID:39245068• R-spondin3 promotes the tumor growth of choriocarcinoma JEG-3 cells., PMID:31851527• R-spondin 3 regulates dorsoventral and anteroposterior patterning by antagonizing Wnt/β-catenin signaling in zebrafish embryos., PMID:24918770• RSPO3 promotes the aggressiveness of bladder cancer via Wnt/β-catenin and Hedgehog signaling pathways., PMID:30329043